DRI Capital Closes Second Drug Royalty Fund
DRI Capital, a private equity firm which invests in drug royalty streams, has closed its second fund with $701 million in capital commitments. It originally targeted $500 million, with Atlantic-Pacific Capital serving as placement agent.
7 April 2010•2 mins read
